Morgan Stanley Initiates Coverage on WuXi PharmaTech (WX)
More News related to WX
- WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
- WuXi PharmaTech (WX) Posts Q3 non-GAAP EPS of $0.24, Tops by 9c
- WuXi PharmaTech Announces Third-Quarter 2009 Results
- Trading Radar for 11/17: Home Depot (HD), Saks (SKS), Target (TGT), Autodesk (ADSK), La-Z-Boy (LZB) Report
- Credit Suisse Downgrades WuXi PharmaTech (WX) to Neutral
More News related to New Coverage
- Longbow Starts KR, WFMI at Buy, SWY, SVU at Neutral
- JMP Starts eBay (EBAY) at Outperform, Amazon (AMZN) at Market Perform
- Sandler O'Neill Initiates Coverage on Mortgage Investment/REIT Stocks
- Meredith Whitney Slaps a Sell on SunTrust Banks (STI)
- Morgan Joseph Initiates Coverage on Three Companies Within the Tower Industry - CCI, SBAC & AMT
Morgan Stanley initiates coverage on WuXi PharmaTech (NYSE: WX) with an Overweight.
WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in China and the United States.
Related Categories
New CoverageStocks Mentioned
-0.34Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
